GHIT Fund Announces New Investments: A Total of 3.29 Billion Yen in Drugs for Malaria, Tuberculosis, Chagas Disease, Lymphatic Filariasis, and Onchocerciasis, Vaccines for Malaria, and Diagnostics for Leishmaniasis and Mycetoma

Project Title

Collaboration Partners

Disease/ Intervention

Stage

Awarded Amount

G2019-208

Continued project

Preparatory phase II for the malaria vaccine candidate NPC-SE36/CpG

RIMD, Osaka University, Nobelpharma Co., Ltd. (NPC), European Vaccine Initiative (EVI), Groupe de Recherche Action en Santé (GRAS)

Malaria

Vaccine

Phase 1 Clinical Development

¥187,077,716 (US $1,709,721)

G2019-213

New project

Production, validation and use of Leishmanin skin test (LST) for detection of Leishmania exposure and immunity

Institute of Tropical Medicine (NEKKEN) Nagasaki University, The Ohio State University, McGill University, Gennova Biopharmaceuticals, US-FDA

Leishmaniasis

Diagnostic

Product Design

¥225,769,996 (US$2,063,334)

G2019-215

New project

Preclinical and Clinical Development of SJ733, a Novel PfATP4 Inhibitor for the Treatment of Severe Malaria

Eisai Co., Ltd., University of Kentucky

Malaria

Drug

Preclinical Development

¥559,009,168 (US $5,108,839)

G2019-219

Continued project

Preclinical studies of potent Gwt1p inhibitor toward IND for antimalarial agent with novel mechanism of action

Eisai Co. Ltd., Medicines for Malaria Venture (MMV)

Malaria

Drug

Preclinical Development

¥682,839,480 (US$6,240,536)

G2019-202

Continued project

Development of AWZ1066S, A Small Molecule anti-Wolbachia Candidate Macrofilaricide Drug

Eisai Co., Ltd., Liverpool School of Tropical Medicine (LSTM), University of Liverpool

Lymphatic filariasis, Onchocerciasis

Drug

Preclinical Development

¥433,581,260 (US$ $3,962,541)

G2019-205

Continued project

Preclinical development of malaria transmission-blocking vaccine candidate Pfs230D1+ formulated with SA-1 adjuvant

Ehime University, Sumitomo Dainippon Pharma Co., Ltd., PATH

Malaria

Vaccine

Preclinical Development

¥500,728,372 (US$4,576,205)

G2019-209

Continued project

Lead optimization of a candidate series active against Chagas Disease

Daiichi Sankyo Company Limited, Drugs for Neglected Diseases initiative (DNDi)

Chagas disease

Drug

Lead Optimization

¥431,856,560 (US $3,946,779)

H2019-201

Continued project

Hit-to-Lead Development of Phenotypic Screening Hits

Chugai Pharmaceutical Co., Ltd., The Global Alliance for TB Drug Development

Tuberculosis

Drug

Lead Identification

¥95,315,987 (US$871,102)

T2019-254

New project

Development of a novel Pvs25 nucleoside-modified mRNA vaccine that induces potent and long-lasting transmission blocking immunity

Ehime University, Mahidol University, University of Pennsylvania

Malaria

Vaccine

Technology Platform Identification

¥96,077,193 (US$878,059)

T2019-252

New project

Made-in-Japan next-generation vaccine platform effective for multistage Plasmodium for infants

Kanazawa University, Hokkaido University, Jichi Medical University, Toyama University, University of Cambridge

Malaria

Vaccine

Concept Development

¥52,690,000 ($481,539)

T2019-260

New project

MycEXomics aims to develop a field-friendly point-of-care diagnostic test for mycetoma

RIKEN, Mycetoma Research Centre (MRC), University of Khartoum, Erasmus University Medical Center, Hospital General de Mexico

Mycetoma

Diagnostics

Concept Development

¥28,593,793 (US$261,321)

G2019-208

Collaboration Partners

RIMD, Osaka University, Nobelpharma Co., Ltd. (NPC), European Vaccine Initiative (EVI), Groupe de Recherche Action en Santé (GRAS)

Disease

Malaria

Intervention

Vaccine

Stage

Phase 1 Clinical Development

Awarded Amount

¥187,077,716 (US $1,709,721)

Status

Continued project

Summary

SE36 is a blood stage malaria vaccine candidate that primarily targets young children in endemic areas to reduce morbidity and mortality due to malaria. Though in principle all stages of parasite development are potential vaccine targets, the blood stage is the one that causes the symptoms of malaria and its complications, and thus has a public health impact. A blood-stage vaccine, either alone or as a component of a multi-stage vaccine, is needed to protect against clinical or epidemic malaria. Early stage clinical trials have demonstrated that the BK-SE36 vaccine, SE36 recombinant protein and aluminium hydroxide gel, has acceptable reactogenicity, has no unexpected safety signals and was immunogenic. Vaccine responders experienced less malaria infection and have lower risk of developing clinical symptoms.  Moreover, a better immune response was achieved in Japanese adults when CpG-ODN (K3) adjuvant was added to the formulation. A safety and immunogenicity phase Ib trial is currently underway in adults to 1-year old children in Burkina Faso with this new formulation. Preliminary results do not indicate unexpected safety concerns. This project builds on these initial trials and allows the next step in further clinical development, before initiation of phase II proof-of-concept clinical trial.

Test the quality of a new and larger batch of SE36 vaccine adsorbed on aluminium hydroxide  (NPC-SE36 vaccine), manufacture new CpG-ODN (K3) adjuvant GMP lot; and select sites and prepare protocol for phase IIb clinical trial. Successful development of a large-scale formulation will enable us to have full evaluation of GMP produced vaccine that can be used for multi-site trials. Moreover, a well-designed phase IIb protocol with selected clinical sites ready to implement the phase IIb clinical trial would address the safety and efficacy of NPC-SE36 in a malaria endemic area. 

The project aims to: 1) Conduct pre-clinical studies on the new GMP lot of NPC-SE36 to show suitable formulation for clinical trial testing and importation. 2) Deliver a new GMP lot of CpG-ODN (K3) as adjuvant for clinical trials. 3) Select phase IIb clinical trial sites and prepare clinical trial documentation.

Project Detail

https://www.ghitfund.org/investment/portfoliodetail/detail/157/en

G2019-213

Project Title

Production, validation and use of Leishmanin skin test (LST) for detection of Leishmania exposure and immunity

Collaboration Partners

Institute of Tropical Medicine (NEKKEN) Nagasaki University, The Ohio State University, McGill University, Gennova Biopharmaceuticals, US-FDA

Disease

Leishmaniasis

Intervention

Diagnostics

Stage

Product Design

Awarded Amount

¥225,769,996 (US$2,063,334)

Status

New project

Summary

The leishmaniases comprise a number of diseases caused by obligate intracellular parasites of the genus Leishmania that is transmitted by the bites of infected sandflies. With over 350 million people worldwide at risk of contracting leishmaniasis and, the WHO classifies leishmaniasis as a neglected tropical disease. The leishmanin skin test (LST) was used for decades to determine exposure and immunity to Leishmania infection but the leishmanin antigen used in the LST is no longer available. There are compelling reasons to bring back the LST. Firstly, the LST could identify districts and villages where there is active or past transmission. This information will help to support visceral leishmaniasis elimination programs. Second, since promising vaccines are advancing, the LST would be an effective surrogate marker to help determine vaccine efficacy.

The objectives of this proposal are to: 1. Produce and determine the stability of the L. donovani antigen (Leishmanin antigen). 2. Validate the Leishmania donovani LST leishmanin antigen in immune animals. 3. Validate the LST in visceral leishmaniasis cured and asymptomatic infected individuals.

A protocol for making Leishmanin antigen from L. donovani parasites will be established and GMP grade Leishmanin will be produced for the Leishmanin skin test (LST). Pre-clinical animal models of visceral leishmaniasis in hamsters and cutaneous leishmaniasis in mice will be used to test Leishmanin antigen and validate LST for detection of latent infection and immunity. Immune responses will also be analyzed in these pre-clinical animal models. After completion of animal studies, LST will be validated in visceral leishmaniasis patients as well as asymptomatic individuals from endemic regions.

Project Detail

https://www.ghitfund.org/investment/portfoliodetail/detail/159/en

G2019-215

Project Title

Preclinical and Clinical Development of SJ733, a Novel PfATP4 Inhibitor for the Treatment of Severe Malaria

Collaboration Partners

Eisai Co., Ltd., University of Kentucky

Disease

Malaria

Intervention

Drug

Stage

Preclinical Development

Awarded Amount

¥559,009,168 (US $5,108,839)

Status

New project

Summary

Severe malaria (SM) is a medical emergency requiring immediate parenteral or enteral treatment. SM affects two million people per year. The current WHO treatment of choice is IV Artesunate (AS), available in 34 developing countries. IV AS is not registered in the US, Europe, Australia, Japan, and many other countries. Other SM treatments have significant liabilities (efficacy/tolerability). SJ733 is an antimalarial entering Phase 2 for oral 3-day treatment of non-severe malaria. In humans, SJ733 is active against blood and sexual stages and possesses an excellent safety profile. SJ733 demonstrated rapid parasite killing in a Phase 1b human challenge. Animal models indicate a lack of embryofetal developmental (EFD) toxicity. SJ733's clinical profile makes SJ733 a strong candidate for the treatment of SM.

The project objectives are:

1)  Manufacture a GMP lot of the current SJ733 drug substance to provide enough material to carry out the proposed preclinical and clinical studies.

2)  Conduct IND-enabling bridging GLP dog toxicity studies to establish a therapeutic window when SJ733 is administered via an intravenous route.

3)  Carry out formulation studies and manufacture of drug product to support development of SJ733 for intravenous (IV) bolus and continuous infusion administration.

4)  Submit an Investigational New Drug (IND) filing to enable first-in-human studies of IV SJ733.

5)  Carry out a Phase 1a trial using IV SJ733 to establish safety and tolerability of both bolus and continuous infusion administration routes.

We will explore SJ733 as a novel treatment for SM. Formulation studies will help select the lead formulation with the optimal dose volume for parental use. Preclinically, the dog was the most sensitive toxicology species. Therefore, GLP dog toxicity studies will bridge from existing IND to the proposed route and schedule. The clinical work will focus on examining safety, tolerability, and pharmacokinetics for two schedules: a bolus IV schedule mirroring AS use and a continuous infusion schedule more closely related to the IV quinine schedule.

Project Detail

https://www.ghitfund.org/investment/portfoliodetail/detail/160/en

G2019-219

Project Title

Preclinical studies of potent Gwt1p inhibitor toward IND for antimalarial agent with novel mechanism of action

Collaboration Partners

Eisai Co. Ltd., Medicines for Malaria Venture (MMV)

Disease

Malaria

Intervention

Drug

Stage

Preclinical Development

Awarded Amount

¥682,839,480 (US$6,240,536)

Status

Continued project

Summary

Malaria is a mosquito-borne, life-threating infectious disease caused by Plasmodium protozoa parasites. An estimated 405,000 people died in 2018, mainly children in African countries. The current standard of care for the treatment of malaria typically involves combination therapy with artemisinin derivatives. However, there is evidence of emerging resistance to artemisinin and its partner drugs in some countries such as Cambodia, Thailand, Myanmar and Vietnam. This highlights the urgent need for new classes of compounds with novel mechanisms-of-action (MoA) to treat resistant strains of malaria parasites and support the global malaria eradication strategy. In this project, we aim to conduct Investigational New Drug(IND)-enabling Good Laboratory Practice (GLP) preclinical studies on an antimalarial candidate compound with a well-characterized and novel MoA. Glycosylphosphatidylinositol (GPI) is a common moiety in all eukaryotes which has a role in anchoring many proteins to the cell surface. Gwt1p, one of the essential enzymes in the GPI biosynthesis pathway, was identified by Eisai as a novel target for an antifungal drug. After conducting discovery research, Eisai discovered E1210, an antifungal drug clinical candidate, and found that the GWT1 gene encoding Gwt1p enzyme is highly conserved among eukaryotes, including Plasmodium protozoa, the etiological pathogens for malaria. Eisai has screened an internal compound library targeting fungal Gwt1p and found a hit compound with inhibitory activities on plasmodial Gwt1p. This compound showed anti-Plasmodium activities in vitro and in vivo and was subjected to chemical modification in GHIT Hit-to-Lead and Lead Optimization Platforms. MMV and Eisai succeeded in creating the candidate compound with improved anti-Plasmodium activity and the long half-life required for single-dose malaria treatment.

The objective of this proposal is to complete preclinical development and IND-enabling GLP studies with a candidate identified in a project funded through the GHIT grant G2017-109.

The current synthetic route will be optimized in a collaboration between Charles River's medicinal chemists and Eisai's process chemists, and a salt form screening will be conducted. Based on the optimized route, Eisai will focus on the following specific objectives:

1)  Manufacture the drug substance required for preclinical studies and phase I trials. The drug substance for preclinical studies will be released around year 1.

2)  Manufacture drug product for phase I trial by the end of the second year.

3)  Conduct preclinical DMPK and safety studies required for First-in-Human (FiH) study submission, such as GLP  preclinical toxicity in rodents and non-rodents, genotoxicity, safety pharmacology, metabolite identification in the second year.

4)  Validate the bioanalytical method to support clinical trials.

5)  Prepare for submission to conduct FiH studies in March 2022.

MMV will also conduct in vivo evaluations to identify possible partner drugs using a humanized murine model. After these studies, MMV will support the selection of sites for phase I FiH and a Volunteer Infection Study, the preparation of the study protocols, the Investigator's Brochure, the Investigational Medicinal Product Dossier (IMPD) and other documentation required for FiH submission in collaboration with Eisai.

Project Detail

https://www.ghitfund.org/investment/portfoliodetail/detail/161/en

G2019-202

Project Title

Development of AWZ1066S, A Small Molecule anti-Wolbachia Candidate Macrofilaricide Drug

Collaboration Partners

Disease

Lymphatic filariasis, Onchocerciasis

Intervention

Drug

Stage

Preclinical Development

Awarded Amount

¥433,581,260 (US$ $3,962,541)

Status

Continued project

Summary

the manufacture of sufficient quantity of the drug candidate to the required quality,

application and granting of permission to conduct the clinical trial 

https://www.ghitfund.org/investment/portfoliodetail/detail/155/en

G2019-205

Project Title

Preclinical development of malaria transmission-blocking vaccine candidate Pfs230D1+ formulated with SA-1 adjuvant

Collaboration Partners

Ehime University, Sumitomo Dainippon Pharma Co., Ltd., PATH

Disease

Malaria

Intervention

Vaccine

Stage

Preclinical Development

Awarded Amount

¥500,728,372 (US$4,576,205)

Status

Continued project

Summary

Malaria remains one of the leading causes of deaths in young African children. New tools are urgently needed to ensure global control, elimination, and eventual eradication goals are met; our vaccine approach has the potential to serve as one such transformational tool. This proposal seeks support for the preclinical development of a vaccine candidate that blocks parasite transmission from human to mosquito.

The goal of this proposal is to generate all the preclinical information necessary to advance a novel candidate Plasmodium falciparum (malaria) vaccine to the clinical testing stage. This transmission-blocking vaccine (TBV) incorporates an optimized immunogen, Pfs230D1+ formulated with novel TLR7 adjuvant (SA-1). At the end of the project, the partners will be ready for clinical phase manufacturing and the filing of an Investigational New Drug (IND) application to the US Food and Drug Administration (US FDA).

This project is a continuation of a GHIT Fund grant (T2016-207) in which the optimal region of the Pfs230 protein was identified for inclusion in a TBV. The current project includes the generation of the high-quality vaccine and adjuvant suitable for performance of definitive safety/toxicology studies. Contact with the US FDA will be made to assure that our plans are appropriate for testing of both a novel vaccine and adjuvant.

Project Detail

https://www.ghitfund.org/investment/portfoliodetail/detail/156/en

G2019-209

Project Title

Lead optimization of a candidate series active against Chagas Disease

Collaboration Partners

Daiichi Sankyo Company Limited, Drugs for Neglected Diseases initiative (DNDi)

Disease

Chagas disease

Intervention

Drug

Stage

Lead Optimization

Awarded Amount

¥431,856,560 (US $3,946,779)

Status

Continued project

Summary

Chagas disease, also known as American trypanosomiasis, is a potentially life-threatening illness caused by Trypanosoma cruzi (T. cruzi). About 6 to 7 million people worldwide are estimated to be infected mainly in Latin American countries where the disease is endemic. Existing drugs for Chagas diseases are associated with serious side effects and suboptimal efficacy for chronic Chagas patients. Drugs for Neglected Diseases initiative (DNDi) and Daiichi Sankyo Co., Ltd. (DS) have been collaborating since early 2016 on the development of a totally new orally active drug with objective to deliver a safe and efficacious treatment for people affected by Chagas disease.

This specific 2-year project aims at engineered out via Lead Optimization this promising class of compounds into one optimized lead candidate for Chagas Disease and at elucidating its mechanism of action by end Q1 2022. This optimized lead candidate shall meet the criteria of the Chagas Disease Target Candidate Profile (TCP) defined by DNDi.

The project team has developed a tailored-to-the needs assay cascade to address the development of this series. Basically, compounds with suitably balanced T. cruzi activity, selectivity and metabolic stability in vitro profiles will be considered as candidates for pharmacokinetic studies. Provided sufficient drug exposure is reached in animals used in those studies, compounds will then be tested in a Chagas acutely infected mouse assay model to assess its ability to clear an established T. cruzi infection targeting a non-detectable level of T. cruzi parasites at end of treatment. Compounds meeting this latter criterion as well as fulfilling a few additional safety-related requirements related to in vitro testing will be tested in the Chagas chronically infected assay model to assess their ability to clear an established T. cruzi chronic infection. Compounds able to sustainably clear out T. cruzi infection in this assay will be considered as curative and meet the Optimized Lead candidate stage criteria. Safety studies for those candidates will be completed in parallel or right after efficacy studies. The relationship between drug dosing and efficacy will be deduced from PK and PD studies conducted on a few carefully selected candidates using adequate treatment regimens and modeling to identify the pharmacokinetic parameters driven efficacy in vivo. Safety and tolerability data will be considered to define the most appropriate dose regimen to be used in PK and PD studies. Various medicinal chemistry strategies will be applied to efficiently optimize the chemical series addressing the identified liabilities including metabolic stability. To manage and mitigate risks of lead molecules effectively, careful assessment of physicochemical properties, in vitro ADME (absorption, distribution, metabolism, and excretion) properties, in vivo pharmacokinetics, in vitro and in vivo safety, and formulation will be performed in parallel with routine in vitro parasitological assay.

Project Detail

https://www.ghitfund.org/investment/portfoliodetail/detail/158/en

H2019-201

Project Title

Hit-to-Lead Development of Phenotypic Screening Hits

Collaboration Partners

Chugai Pharmaceutical Co., Ltd., The Global Alliance for TB Drug Development

Disease

Tuberculosis

Intervention

Drug

Stage

Lead Identification

Awarded Amount

¥95,315,987 (US$871,102)

Status

Continued project

Summary

Chugai Pharmaceutical Co., Ltd. and TB Alliance collaborated in a program under a sponsorship of the GHIT. A set of natural products were discovered to have potent activity against Mycobacterium tuberculosis (M.tb), and they appear to be unprecedented in the pipelines for TB drug development. They are now ready to be examined further in the next phase of drug development.

The main objective of this project is to develop compounds we discovered through our process of testing natural products against M.tb, the bacteria that causes TB. This involves not only improving the potency of the compounds against M.tb but improving their pharmacokinetic properties and safety liabilities so that we can demonstrate their activity in animal models. We plan to identify a compound at the end of the two-year period to move to the next phase of development, known as lead optimization.

The original hits were discovered from natural products that were produced by microorganisms through a fermentative process. For the next step, instead of fermentation processes, we plan to employ synthetic chemistry to prepare a large number of analogues in a relatively short time. The new analogues will be tested for potency, metabolic properties, safety, and eventually efficacy in mice. We are already investigating how these hit compounds kill M.tb and once this is deciphered, it should inform the design of new analogues by taking the structure of the target biomolecule into account.

Project Detail

https://www.ghitfund.org/investment/portfoliodetail/detail/151/en

T2019-254

Project Title

Development of a novel Pvs25 nucleoside-modified mRNA vaccine that induces potent and long-lasting transmission blocking immunity

Collaboration Partners

Ehime University, Mahidol University, University of Pennsylvania

Disease

Malaria

Intervention

Vaccine

Stage

Technology Platform Identification

Awarded Amount

¥96,077,193 (US$878,059)

Status

New project

Summary

Vivax malaria is recognized as a leading neglected tropical disease worldwide. Plasmodium vivax parasite poses a major challenge to malaria elimination due to its ability to cause recurring blood infections. These 'relapses' of malaria are caused by hypnozoites, the dormant form of the parasite in the liver. Therefore, hypnozoites is considered as the major challenge towards malaria elimination in vivax endemic countries. The only drugs available to clear hypnozoites are primaquine and tafenoquine. However, these drugs cause severe hemolysis in people with G6PD deficiency and are difficult to deploy in large scale to drive vivax malaria elimination. Vaccination is an alternative and the most cost-effective way to control malaria, however, malaria vaccine which target P. vivax has not been developed.

The goal of this project is to develop a novel nucleoside-modified mRNA vaccine targeting Pvs25 protein that induces potent and long-lasting transmission blocking immunity and is able to interrupt transmission of P. vivax from human to mosquito.

To achieve our objective, we will combine our experiences in malaria vaccine development (Mahidol and Ehime Universities) and mRNA vaccine technology (the University of Pennsylvania) to develop nucleoside-modified mRNA vaccines that block transmission of P. vivax, a major malaria parasite outside Africa. The vaccine target is the protein Pvs25 which is expressed on the surface of the transmission-stage parasite, a well-validated target. In our vaccines, nucleoside-modified mRNA encoding Pvs25 will be delivered by lipid nanoparticles (LNP), an approach which has been shown to be highly effective in other vaccines. Several mRNA-LNP formulations will be tested in animals to identify the best candidate. Several routes of administrations and immunization schedules will also be explored. Vaccine efficacy will be determined by the ability of the immune sera of immunized animals to block mosquito infection using membrane feeding assay with P. vivax parasites isolated in Thailand. In addition to developing a new transmission blocking vaccine, we will also investigate the immune mechanism that results in transmission blocking activity.

Project Detail

https://www.ghitfund.org/investment/portfoliodetail/detail/153/en

T2019-252

Project Title

Made-in-Japan next-generation vaccine platform effective for multistage Plasmodium for infants

Collaboration Partners

Kanazawa University, Hokkaido University, Jichi Medical University, Toyama University, University of Cambridge

Disease

Malaria

Intervention

Vaccine

Stage

Concept Development

Awarded Amount

¥52,690,000 ($481,539)

Status

New project

Summary

As a valuable addition to sustain realistic and affordable malaria control, a candidate anti-malarial vaccine must perform safely and efficiently during neonatal and early life vaccination in resource-poor settings. Accordingly, such a malaria childhood vaccine would ideally be tailored for integration into the current Expanded Programme on Immunization (EPI) vaccines. At the same time, we should consider host factors which may severely impair vaccine efficacy. Because RTS,S vaccine can induce higher protective immune response for volunteers in developed countries, compared with those in developing countries and infants in Africa. We (and others) hypothesize that helminths and maternal antibodies are critical host factors to be considered when developing a malaria vaccine. Significant numbers of individuals living in tropical areas are demonstrably co-infected with helminths, which are known to adversely affect immune responses to a number of different existing vaccines. In addition to the host factors, there is an inevitable risk involved in monovalent vaccines such as RTS,S. Gene polymorphisms and mutations may cause drastic reduction of protective efficacy, resulting in vaccine failure. A recent study has reported that vaccines capable of inducing both antibodies against pre-erythrocytic stage (protection) and sexual-stage parasites (transmission blocking [TB]) possess strong synergistic effects on parasite reduction in prevalence.

Development of a highly effective and durable next-generation multistage malaria vaccine effective against both pre-erythrocytic stage and sexual-stage parasites based on two viral vectors for African infants with pre-existing helminths and maternal antibodies. It is proven that successful implementation of this strategy would lead to enhanced parasitic elimination.

Two viral-vectored vaccines expressing both pre-erythrocytic-stage and sexual-stage antigens will be generated. Protective and transmission blocking (TB) efficacies of the heterologous prime-boost immunization regimen will be assessed by sporozoite challenge and Direct Membrane Feeding Assay (DMFA) in a robust and proven mouse model, and then the regime will be further optimized (e.g., dose, route, interval and outbred mice). Desired protection rate >90%. Surrogate markers responsible for protection will be identified. This will be key to allow efficient and robust measurements of efficacy. Humoral and cellular immune responses induced by the heterologous prime-boost immunization regimen will be assessed.

Project Detail

https://www.ghitfund.org/investment/portfoliodetail/detail/152/en

T2019-260

Project Title

MycEXomics aims to develop a field-friendly point-of-care diagnostic test for mycetoma

Collaboration Partners

RIKEN, Mycetoma Research Centre (MRC), University of Khartoum, Erasmus University Medical Center, Hospital General de Mexico

Disease

Mycetoma

Intervention

Diagnostics

Stage

Concept Development

Awarded Amount

¥28,593,793 (US$261,321)

Status

New project

Summary

Mycetoma is a neglected tropical disease of the subcutaneous tissue and is characterized by large tumor-like lesions. It is caused by more than 70 different causative agents, but four of these are responsible for 79.5% of all mycetoma cases world-wide. Appropriate treatment outcome depends on proper identification of the causative organism. The current mycetoma diagnostics tools are tedious, invasive of low sensitivity and specificity and expensive. Presently there is no point-of-care diagnostic test for mycetoma.

To identify species-specific markers for the 4 most common causative agents of mycetoma in urine and plasma of mycetoma patients

In order to identify species-specific markers a five step-approach will be taken

1)  Urine and plasma will be isolated from patients with mycetoma

2)  The causative agent will be identified by PCR

3)  Exosomes will be isolated from urine and plasma, as they will most likely contain species specific markers

4)  RNA will be isolated from the exosomes and sequenced

5)  The transcriptomes will be profiled and markers identified

The markers identified in MycEXomics can later be used to develop Point-of-Care diagnostic tools to detect early cases of mycetoma.

Project Detail

https://www.ghitfund.org/investment/portfoliodetail/detail/154/en